DNAP conference is this month, read about here...
DNAP invited to present at 8th Annual BioPartnering Europe
Conference
July 27, 2000. - DNAPrint genomics (Pink Sheets: "DNAP") announced today that it is one of
only five emerging companies that has been invited to present at the 8th Annual BioPartnering
Europe (BPE) conference held in London October 16-17th. The conference is the premier
European venue for showcasing innovative biophamaceutical and diagnostics companies from
Europe, North America, Japan and the rest of the world. The theme of the 8th annual meeting
is "Investing in Electronic R and D: New partnerships arising from the convergence of
chemistry, biology, computing and automation." Presentation at the conference is by invitation
only and Emerging Company Presentation invitations are prestigious. As an Emerging
Company Presenter, DNAPrint genomics will present a company profile before a captive
audience in the main plenary hall. DNAprint genomics will present information about its
science and technology, partnering strategy, developmental programs and capabilities,
commercialization plans and product opportunities
The purpose of the meeting is to bring together less well-known companies and established
biopharmaceutical companies to explore opportunities for mutually beneficial partnerships and
collaborations. The conference is sponsored by Technology Vision Group LLC,
(www.biopartnering.com/bpe) and will host 100 innovative biopharmaceutical and diagnostics
companies, and several hundred more established companies. Last years meeting involved
416 companies from 22 different countries.
About DNAPrint genomics
DNAPrint genomics, Inc. will provide practitioners of genomics research and personalized
medicine with a comprehensive system for disease dissection and patient classification.
Health care professionals and biopharmaceutical scientists will be able to use the company's
system, through a combination of on-site hardware/software placement and ASP
(application-service provider) resources, to draw highly sophisticated conclusions and
associations between genotype (SNP an haplotype) data and phenotypic traits (such as drug
response). The analytical heart of the system is a collection of sophisticated algorithms that
enable a quantitative and multivariate dissection of high-density genotype matrices in complex
genetic terms for various human diseases and drug-interaction traits. The system uses a
variety of novel mathematical modeling and programming techniques, which comprise the bulk
of the companies budding intellectual property portfolio. The company is applying it's
informatics platform to real-world pharmacogenomic study in order to build a portfolio of
pharmacogenomics "solutions". These "solutions" mathematically express the nature of the
genotype-phenotype relationship for a given drug, and will be used by future DNAprint
genomics customers as a template against which they can screen an unknown. The company
has already filed patent applications for a genetic analysis reagent that confers considerable
advantages for high-throughput DNA sequencing and genotyping. The company intends to
patent the application of its informatics platform to the field of genomic research and for
personalized medical applications. The company will also patent each pharmacogenomic and
disease "solution" that it generates, as a unique, predictive and preventative diagnostic or
"diagnomic" product.. DNAPrint genomics Inc. was founded by a group of scientists with
research and commercial experience in high-level mathematical modeling, programming and
molecular genetics. For more information about the company, please visit www.dnaprint.com.
Copyright DNAprint genomics © 2000
1748 Independence Blvd. Ste D1
Sarasota, Florida 34234
